fda advisory committee meeting to discuss nda for amx0035 for the treatment of als amylyx pharmaceuticals inc amlx today announced that nasdaq has halted trading of the companys common stock the us food and drug administrations fda peripheral and central nervous system drugs advisory committee pcnsdac is meeting today to review the new drug application nda for amx0035 sodium phenylbutyrate pb and taurursodiol turso also known as ursodoxicoltaurine for the treatment of amyotrophic lateral sclerosis als the advisory committee meeting is scheduled for 1000 am et the briefing materials can be found on the fda website here the prescription drug user fee act pdufa target action date for the amx0035 nda is june 29 2022 amylyx pharmaceuticals inc is a clinicalstage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis als and other neurodegenerative diseases for more information visit wwwamylyxcom and follow us on linkedin and twitter for investors please visit wwwinvestorsamylyxcom statements contained in this press release regarding matters that are not historical facts are forwardlooking statements within the meaning of the private securities litigation reform act of 1995 as amended because such statements are subject to risks and uncertainties actual results may differ materially from those expressed or implied by such forwardlooking statements such statements include but are not limited to statements regarding the potential approval of amx0035 for the treatment of als the potential of amx0035 as a treatment for als and expectations regarding our longerterm strategy any forwardlooking statements in this statement are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forwardlooking statements risks that contribute to the uncertain nature of the forwardlooking statements include regulatory developments and expectations regarding the timing of fda review of amx0035 for the treatment of als and the impact that the ongoing covid19 pandemic will have on fda review timelines as well as those risks and uncertainties set forth in amylyx united states securities and exchange commission filings all forwardlooking statements contained in this press release speak only as of the date on which they were made amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made